SK Biopharmaceuticals Co., Ltd has reported a sharp rise in first-quarter sales and shifted to an operating profit on the back of rising prescriptions of Xcopri (cenobamate) in the US and the receipt of a milestone payment for the marketing authorization of the epilepsy drug in Europe.
On a consolidated basis, the company’s Q1 sales jumped to KRW140bn ($123.8m) from KRW16.1bn in the previous quarter. It also...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?